[18F]-fluoro-ethyl-l-tyrosine PET: A valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma

Neuro-Oncology

Volumn 15, Issue 3, 2013, Pages 341-351

  Hutterer, Markus ^a,b   Nowosielski, Martha ^a   Putzer, Daniel ^b   Jansen, Nathalie L ^d   Seiz, Marcel ^b   Schocke, Michael ^a   McCoy, Mark ^c   Göbel, Georg ^b   La Fougère, Christian ^d   Virgolini, Irene J ^b   Trinka, Eugen ^b   Jacobs, Andreas H ^e,f   Stockhammer, Günther ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f Johanniter Krankenhaus   (Germany)

Author keywords

18F FET PET; brain tumor; diagnostic value; glioma; MRI

Indexed keywords

DIAGNOSTIC AGENT; FLUOROETHYL TYROSINE F 18; RADIOISOTOPE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; FLUORODEOXYGLUCOSE F 18; O (2 FLUOROETHYL)TYROSINE; O-(2-FLUOROETHYL)TYROSINE; RADIOPHARMACEUTICAL AGENT; TYROSINE;

ACOUSTIC NEURINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN DAMAGE; BRAIN LYMPHOMA; BRAIN MALFORMATION; BRAIN TUMOR; CANCER PATIENT; CHILD; CLINICAL ASSESSMENT; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORTICAL DYSPLASIA; CRANIOPHARYNGIOMA; DIAGNOSTIC TEST ACCURACY STUDY; DRUG UPTAKE; EPENDYMOMA; FEMALE; GLIOMA; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS ADENOMA; INFLAMMATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MENINGOENCEPHALITIS; NEURILEMOMA; NEUROECTODERM TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PILOCYTIC ASTROCYTOMA; PINEAL BODY TUMOR; POSITRON EMISSION TOMOGRAPHY; RETICULOSARCOMA; RETROSPECTIVE STUDY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TERATOMA; BLOOD BRAIN BARRIER; CANCER GRADING; FOLLOW UP; IMAGE PROCESSING; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SCINTISCANNING; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; GLIOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM GRADING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TYROSINE; YOUNG ADULT;

MLCS; MLOWN;

EID: 84874543727     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos300     Document Type: Article

References (42)

1. Jain R, Scarpace LM, Ellika S, et al. Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J Neurooncol. 2010;96(3):423-431.
2. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42(3):432-445. (Pubitemid 32207394)
3. Floeth FW, Pauleit D, Wittsack HJ, et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg. 2005;102(2):318-327. (Pubitemid 43194083)
4. Stockhammer F, Plotkin M, Amthauer H, van Landeghem FK, Woiciechowsky C. Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas. J Neurooncol. 2008;88(2):205-210.
5. Ullrich R, Backes H, Li H, et al. Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res. 2008;14(7):2049-2055. (Pubitemid 351551115)
6. Pauleit D, Floeth F, Hamacher K, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128(Pt 3):678-687. (Pubitemid 40380202)
7. Tanaka Y, Nariai T, Momose T, et al. Glioma surgery using a multimodal navigation system with integrated metabolic images. J Neurosurg. 2009;110(1):163-172.
8. Plotkin M, Blechschmidt C, Auf G, et al. Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas. Eur Radiol. 2010;20(10):2496-2502.
9. Floeth FW, Stummer W. The value of metabolic imaging in diagnosis and resection of cerebral gliomas. Nat Clin Pract Neurol. 2005;1(2):62-63.
10. Floeth FW, Sabel M, Ewelt C, et al. Comparison of (18)F-FET PET and 5-ALA fluorescence in cerebral gliomas. Eur J Nucl Med Mol Imaging. 2011;38(4):731-741.
11. Grosu AL, Weber WA. PET for radiation treatment planning of brain tumours. Radiother Oncol. 2010;96(3):325-327.
12. Grosu AL, Weber WA, Franz M, et al. Reirradiation of recurrent highgrade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63(2):511-519. (Pubitemid 41317169)
13. Piroth MD, Holy R, Pinkawa M, et al. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastomapatients treated with radiochemotherapy. Radiother Oncol. 2011;99(2):218-224.
14. Piroth MD, Pinkawa M, Holy R, et al. Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme-a dosimetric comparison. Radiat Oncol. 2009;4:57.
15. Weber DC, Zilli T, Buchegger F, et al. [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma. Radiat Oncol. 2008;3:44.
16. Weber DC, Casanova N, Zilli T, et al. Recurrence pattern after [(18)F]fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma: a prospective study. Radiother Oncol. 2009;93(3):586-592.
17. Rickhey M, Moravek Z, Eilles C, Koelbl O, Bogner L. 18F-FET-PETbased dose painting by numbers with protons. Strahlenther Onkol. 2010;186(6):320-326.
18. Rickhey M, Koelbl O, Eilles C, Bogner L. A biologically adapted dose-escalation approach, demonstrated for 18F-FET-PET in brain tumors. Strahlenther Onkol. 2008;184(10):536-542.
19. Niyazi M, Geisler J, Siefert A, et al. FET-PET for malignant glioma treatment planning. Radiother Oncol. 2011;99(1):44-48.
20. Galldiks N, Langen KJ, Holy R, et al. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. J Nucl Med. 2012;53(7):1048-1057.
21. Hutterer M, Nowosielski M, Putzer D, et al. O-(2-18F-fluoroethyl)-L- tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med. 2011;52(6):856-864.
22. Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol. 2011;13(3):307-316.
23. Popperl G, Kreth FW, Mehrkens JH, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007;34(12):1933-1942. (Pubitemid 350212135)
24. Dunet V, Rossier C, Buck A, Stupp R, Prior JO. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and metaanalysis. J Nucl Med. 2012;53(2):207-214.
25. Pauleit D, Stoffels G, SchadenW, et al. PET with O-(2-18F-fluoroethyl)-L- tyrosine in peripheral tumors: first clinical results. J Nucl Med. 2005;46(3):411-416. (Pubitemid 43093148)
26. Pauleit D, Stoffels G, Bachofner A, et al. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol. 2009;36(7): 779-787.
27. Pichler R, Dunzinger A, Wurm G, et al. Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? Eur J Nucl Med Mol Imaging. 2010;37(8):1521-1528.
28. Kasper BS, Struffert T, Kasper EM, et al. 18Fluoroethyl-L-tyrosine-PET in long-term epilepsy associated glioneuronal tumors. Epilepsia. 2011;52(1):35-44.
29. Weckesser M, Langen KJ, Rickert CH, et al. O-(2-[18F]fluorethyl)-L- tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging. 2005;32(4):422-429. (Pubitemid 40591174)
30. Floeth FW, Pauleit D, Sabel M, et al. 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med. 2006;47(5):776-782. (Pubitemid 46768440)
31. Pichler R, Wurm G, Nussbaumer K, Kalev O, Silye R, Weis S. Sarcoidosis and radiation-induced astrogliosis causes pitfalls in neuro-oncologic positron emission tomography imaging by O-(2-[18F]fluoroethyl)-L-tyrosine. J Clin Oncol. 2010;28(36):e753-e755.
32. Jacobs A. Amino acid uptake in ischemically compromised brain tissue. Stroke. 1995;26(10):1859-1866.
33. Mehrkens JH, Popperl G, Rachinger W, et al. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol. 2008;88(1):27-35.
34. Giammarile F, Cinotti LE, Jouvet A, et al. High and low grade oligodendrogliomas (ODG): correlation of amino-acid and glucose uptakes using PET and histological classifications. J Neurooncol. 2004;68(3): 263-274. (Pubitemid 38878262)
35. Fortin D, Cairncross GJ, Hammond RR. Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery. 1999;45(6):1279-1291.
36. Jansen NL, Graute V, Armbruster L, et al. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging. 2012;39(6):1021-1029.
37. Galldiks N, Kracht LW, Dunkl V, et al. Imaging of non-or very subtle contrast-enhancing malignant gliomas with [(11)C]-methionine positron emission tomography. Mol Imaging. 2011;10(6):453-459.
38. Floeth FW, Sabel M, Stoffels G, et al. Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions. J Nucl Med. 2008;49(5):730-737. (Pubitemid 351717537)
39. Niyazi M, Geisler J, Siefert A, et al. FET-PET for malignant glioma treatment planning. Radiother Oncol. 2011;99(1):44-48.
40. Kaim AH, Weber B, Kurrer MO, et al. (18)F-FDG and (18)F-FET uptake in experimental soft tissue infection. Eur J Nucl Med Mol Imaging. 2002;29(5):648-654. (Pubitemid 34439325)
41. Rau FC, Weber WA, Wester HJ, et al. O-(2-[(18)F]Fluoroethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging. 2002;29(8):1039-1046.
42. Pauleit D, Floeth F, Tellmann L, et al. Comparison of O-(2-18Ffluoroethyl)-L-tyrosine PET and 3-123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors. J Nucl Med. 2004;45(3):374-381. (Pubitemid 47618609)